124
Participants
Start Date
September 30, 2008
Primary Completion Date
August 31, 2009
Study Completion Date
December 31, 2009
ALD518
ALD518 80 mg on Day 1, Week 8 and Week 16
ALD518
ALD518 160 mg IV on Day 1, Week 8 and Week 16
ALD518
ALD518 360 mg IV on Day 1, Week 8, and Week 16
Infusion of 0.9% Saline without ALD518
Infusion of 0.9% Saline without addition of ALD518
Australian Clinical Research Organisation, Kippa-Ring
Rivercity Hospital Research Centre, Auchenflower
Royal Adelaide Hospital, Adelaide
Palliative Care Launceston General Hospital, Launceston
Clinical Hospital Center Bezanijska Kosa, Belgrade
Clinical Centre Kragujevac, Kragujevac
Yaroslavl Regional clinical Oncology Hospital, Yaroslavl
Saint-Petersburg State Medical University, I.P. Pavlov, Saint Petersburg
St. Petersburg City Oncology Dispensary, Saint Petersburg
SEAROC Cancer Centre, Jaipur
Territorial Clinical Oncology Dispensary, Krasnodar
Stavropol Territorial Clinical, Pyatigorsk
Kailash Cancer Hospital and Research Centre, Gujarat
Professor Dr. I Chiricuta Institute of Oncology and Radiotherapy, Cluj-Napoca
Oradea Clinical County Hospital Medical Oncology Department, Oradea
Republic Oncology Dispensary, Ufa
IndoAmerican Cancer Institute & Research Center, Hyderabad
County Hospital Sibiu Medical Oncology Department, Sibiu
Kidwai Memorial Institute of Oncology, Bangalore
Dr. Kamakshi Memorial Hospital, Pallikaranai
City Clinical Hospital No. 1, Novosibirsk
GKNM Hospital, Pappanaickenpalayam
Mahavir Cancer Sansthan, Patna
Cross Cancer Institute, Edmonton
Atlantic Health Sciences Corporation, Saint John
McGill University, Department of Oncology, Montreal
A. Gvamichava National Cancer Centre, Tbilisi
Union Cancer Prevention Centre, Tbilisi
Medulla Chemotherapy and Immunotherapy Clinic, Tbilisi
Indira Gandhi Institute of Medical Sciences, Patna
Shatabdi Hospital, Mumbai
Curie Manavata Cancer Centre, Nashik
Orchid Nursing Home, Kolkata
Tata Memorial Hospital, Mumbai
Jehangir Clinical Development Centre Pvt. Ltd., Pune
P3 Research LTD, Tauranga
Oddzial Chorob Pluc i Leczenia Raka Pluc, Bydgoszcz
Oddzial Chemioterapii Szpital Morski, Gdynia
II Oddzia Chorob Pluc z Pododdzialem Chemioterapii, Krakow
Oddzial II Chemioterapii Specjalistyczny Szpital, Szczecin
Professor Dr. Al Trestioreanu Institute, Bucharest
Institute of Lung Diseases and TB, Belgrade
Institute for Pulmonary diseases of Vojvodina, Sremska
Lead Sponsor
CSL Behring
INDUSTRY